share_log

Tracon Pharmaceuticals | EFFECT: Others

Tracon Pharmaceuticals | EFFECT: Others

Tracon Pharmaceuticals | EFFECT:其他
美股SEC公告 ·  11/04 06:04

Moomoo AI 已提取核心訊息

Tracon Pharmaceuticals, Inc. has achieved a regulatory milestone with the United States Securities and Exchange Commission (SEC) as of November 1, 2024. The SEC has issued a Notice of Effectiveness for the company, which is a significant step in the regulatory process. The notice, bearing the Accession Number 0000950170-24-119600, corresponds to the Submission Type POS AM. This development is crucial for Tracon Pharmaceuticals as it indicates the SEC's acceptance of an amended registration statement or post-effective amendment, allowing the company to proceed with its plans as outlined in the filing under File Number 333-239574.
Tracon Pharmaceuticals, Inc. has achieved a regulatory milestone with the United States Securities and Exchange Commission (SEC) as of November 1, 2024. The SEC has issued a Notice of Effectiveness for the company, which is a significant step in the regulatory process. The notice, bearing the Accession Number 0000950170-24-119600, corresponds to the Submission Type POS AM. This development is crucial for Tracon Pharmaceuticals as it indicates the SEC's acceptance of an amended registration statement or post-effective amendment, allowing the company to proceed with its plans as outlined in the filing under File Number 333-239574.
tracon pharmaceuticals公司已於2024年11月1日達成與美國證券交易委員會(SEC)的監管里程碑。SEC已發佈了該公司的有效通知,這是監管流程中的重要一步。該通知,附帶着訪問編號0000950170-24-119600,對應於提交類型pos Am. 這一進展對tracon pharmaceuticals至關重要,因爲它表明SEC接受了修訂後的註冊聲明或事後生效修正案,允許公司按照在文件號333-239574下概述的計劃繼續進行。
tracon pharmaceuticals公司已於2024年11月1日達成與美國證券交易委員會(SEC)的監管里程碑。SEC已發佈了該公司的有效通知,這是監管流程中的重要一步。該通知,附帶着訪問編號0000950170-24-119600,對應於提交類型pos Am. 這一進展對tracon pharmaceuticals至關重要,因爲它表明SEC接受了修訂後的註冊聲明或事後生效修正案,允許公司按照在文件號333-239574下概述的計劃繼續進行。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息